Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · IEX Real-Time Price · USD
76.12
+0.71 (0.94%)
At close: Jul 2, 2024, 4:00 PM
76.08
-0.04 (-0.05%)
After-hours: Jul 2, 2024, 7:49 PM EDT
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 25,863 employees as of March 31, 2023. The number of employees increased by 1,068 or 4.31% compared to the previous year.
Employees
25,863
Change (1Y)
1,068
Growth (1Y)
4.31%
Revenue / Employee
$129,502
Profits / Employee
$25,831
Market Cap
12.68B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
Tenet Healthcare | 106,500 |
DaVita | 70,000 |
Viatris | 38,000 |
Revvity | 11,500 |
Medpace Holdings | 5,900 |
Natera | 3,293 |
Bio-Techne | 3,050 |
RDY News
- 6 days ago - Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business - Business Wire
- 4 weeks ago - Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities - Business Wire
- 5 weeks ago - Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire
- 6 weeks ago - Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK - Business Wire
- 2 months ago - Dr. Reddy's Q4 & Full Year FY24 Financial Results - Business Wire
- 2 months ago - Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. - Business Wire
- 3 months ago - Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire
- 5 months ago - Dr. Reddy's Q3 & 9M FY24 Financial Results - Business Wire